Crinetics Pharmaceuticals (CRNX) Research & Development (2017 - 2026)

Crinetics Pharmaceuticals' Research & Development history runs 10 years deep, the most recent figure standing at $100.1 million for Q1 2026.

• In Q1 2026, Research & Development rose 31.27% year-over-year to $100.1 million; the TTM figure through Mar 2026 stood at $355.9 million (up 35.29% YoY), while the FY2025 annual figure was $332.1 million, up 38.27% from the prior year.
• Research & Development was $100.1 million for Q1 2026 at Crinetics Pharmaceuticals, up from $85.1 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $100.1 million in Q1 2026 to a low of $28.3 million in Q1 2022.
• Historically, Research & Development has averaged $57.1 million across 5 years, with a median of $53.3 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Research & Development jumped 61.05% in 2022, then grew 23.17% in 2023.
• A 5-year view of Research & Development shows it stood at $37.0 million in 2022, then gained by 23.22% to $45.6 million in 2023, then soared by 46.04% to $66.6 million in 2024, then rose by 27.77% to $85.1 million in 2025, then climbed by 17.67% to $100.1 million in 2026.
• The last three Research & Development figures came in at $100.1 million (Q1 2026), $85.1 million (Q4 2025), and $90.5 million (Q3 2025), per Business Quant data.